These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28663582)

  • 1. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
    Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
    Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
    Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
    Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
    Li Y; Bouchlaka MN; Wolff J; Grindle KM; Lu L; Qian S; Zhong X; Pflum N; Jobin P; Kahl BS; Eickhoff JC; Wuerzberger-Davis SM; Miyamoto S; Thomas CJ; Yang DT; Capitini CM; Rui L
    Oncogene; 2016 Dec; 35(48):6223-6234. PubMed ID: 27157620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    He L; Chen C; Gao G; Xu K; Ma Z
    Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
    Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
    Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
    Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis.
    Shi C; Zhang H; Wang P; Wang K; Xu D; Wang H; Yin L; Zhang S; Zhang Y
    Cell Death Dis; 2019 Oct; 10(11):815. PubMed ID: 31653826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
    Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun SY
    Cancer Res; 2020 Jun; 80(11):2380-2393. PubMed ID: 32156781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
    DeMars KM; Yang C; Castro-Rivera CI; Candelario-Jalil E
    Biochem Biophys Res Commun; 2018 Feb; 497(1):410-415. PubMed ID: 29448097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.